Munich, Germany, October 12, 2011 / B3C newswire / - Definiens®, the leading Health Image Intelligence™ company, today announced the release of its new Quantitative Digital Pathology portfolio, designed to advance translational research in pathology, specifically in biomarker development. The new portfolio will offer updated versions of Definiens Tissue Studio®, Definiens Developer XD™ as well as the introduction of a novel component, Definiens Image Miner™.
The technology in Definiens’ recently released product suite will provide high accuracy in automatically identifying relevant structures of interest and specific morphology in histology, resulting in a detailed phenotypic fingerprint and biomarker expression profile on a cell-by-cell basis. The large set of descriptors can be correlated against therapy response or patient outcome with the goal of identifying new types of biomarkers of predictive or prognostic value.
Definiens Image Miner™ 1, the novel technology component in this product portfolio, closely integrates data mining with image analysis to accelerate biomarker research. The data mining functionality is based on the same revolutionary Cognition Network Technology used in Definiens’ well-established image analysis solutions. Definiens Image Miner™ 1 provides a substantial productivity increase when profiling tissue probes for clinically or diagnostically relevant differences in morphology or biomarker expression. Development and quality control are supported by seamless links between data points and the visual inspections of associated regions in the tissue.
“We expect the tight integration of our new data-mining engine with the significantly updated image analysis solutions to substantially increase productivity and assay quality in tissue-based biomarker development,” says Dr. Martin Baatz, Vice President of Marketing at Definiens. “We consider this a major step on the way to turning pathology into a quantitative discipline.”
Also included in the new portfolio is Definiens Developer XD™ 2, the most powerful development environment for automated image analysis that addresses a wide scope of functions in biomedical image analysis with unprecedented depth and accuracy. Developer XD™ 2 will be the solution of choice for highly advanced or customized analysis tasks of digital tissue slides. This updated version addresses a series of requirements suggested by the user community including very large data processing and machine learning functionality.
The highly popular product of the suite is Definiens Tissue Studio® 3, which is an updated version of the company’s leading Image Analysis Solution for Quantitative Digital Pathology. It combines highly detailed quantification of tissue specimen with a straightforward and fast out-of-the-box configuration workflow. New features include an improved detection of regions of interest, classification of nuclear morphology and an angiogenesis module.
After exploring the new Definiens Tissue Studio® 3 during the early access program, Mark Lloyd, Supervisor of Analytical Microscopy Core Facility at Moffitt Cancer Center, says: “I can be difficult to please regarding image analysis of histological samples, but this is the best commercial product I have used to date. This includes workflow and usability, as well as function and flexibility.” And Dr. Tom Nifong, VP CLIA Services at Metamark Genetics, adds: “The Composer Technology for automatic detection of regions of interest performed great. It was able to identify tumor, stroma and artifacts in my fluorescence samples. I was really impressed by the improvement in accuracy and speed of the nucleus detection. Fantastic job!”
For more information about the new products, please visit quantitative-digital-pathology.definiens.com or register for the launch webinar. The products will also be presented at the upcoming International Definiens Symposium at the Moffitt Cancer Center, FL, Oct. 17 and 18.
Definiens is a leading Health Image Intelligence™ company that develops software solutions for biomedical image analysis, data mining and clinical decision support. The company’s software analyzes images from cell-based assays, whole tissue slides and full body scans and allows users to correlate this information with data derived from other sources. By automating analysis workflows and generating new knowledge, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and medical professionals with deeper insights, faster results and better decision support. Harnessing the power of image intelligence, Definiens supports the development of personalized medicine and aims to significantly improve the quality of patients’ lives.
Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at www.definiens.com.
Dr. Martin Baatz
Vice President Marketing
212.679.3300 ext. 120